ArticleInternational journal of molecular sciences2021
CD163 as a Potential Biomarker of Monocyte Activation in Ischemic Stroke Patients.
Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Blood glucose mediation of the association between SIRI and mortality in T2DM complicated with ischemic stroke.Scientific reports · 2026Article
- Gene expression profiling of whole blood samples following marathon running in non-elite athletes.Biology of sport · 2026Article
- Serum sCD163 as a potential biomarker for predicting poor functional outcome at 3 months in acute ischemic stroke without reperfusion: a prospective study.Frontiers in immunology · 2026Article
- Innate Immune Cell Profiling in Peripheral Blood Mononuclear Cells of Patients with Moyamoya Disease.Inflammation · 2025Article
- Analysis of ferroptosis-related genes in cerebral ischemic stroke via immune infiltration and single-cell RNA-sequencing.BMC medical genomics · 2025Article
- Monocyte-red blood cell crosstalk supports clearance and heme metabolism in sickle cell anemia.Frontiers in immunology · 2025Article
- Thrombo-pathologic features and prognosis of acute ischemic stroke patients treated with remedial stent implantation.Frontiers in neurology · 2025Article
- Expression of miR-155 in monocytes of people with migraine: association with phenotype, disease severity and inflammatory profile.The journal of headache and pain · 2024Article
- Advancing stroke recovery: unlocking the potential of cellular dynamics in stroke recovery.Cell death discovery · 2024Review
- Effects of peripheral blood cells on ischemic stroke: Greater immune response or systemic inflammation?Heliyon · 2024Review
- Differential expression of Semaphorin-7A /CD163-positive macrophages in large artery and cardiogenic stroke.BMC neurology · 2024Article
- Utility of peripheral blood monocyte subsets, circulating immune complexes and serum cytokines in assessment of SLE activity: an observational, cross-sectional study.Clinical rheumatology · 2024Observational
- Uncovering the dual roles of peripheral immune cells and their connections to brain cells in stroke and post-stroke stages through single-cell sequencing.Frontiers in neuroscience · 2024Review
- Characterization of the Involvement of Tumour Necrosis Factor (TNF)-α-Stimulated Gene 6 (TSG-6) in Ischemic Brain Injury Caused by Middle Cerebral Artery Occlusion in Mouse.International journal of molecular sciences · 2023Article
- Friends or foes: The mononuclear phagocyte system in ischemic stroke.Brain pathology (Zurich, Switzerland) · 2023Review
- Tumor Necrosis Factor (TNF)-α-Stimulated Gene 6 (TSG-6): A Promising Immunomodulatory Target in Acute Neurodegenerative Diseases.International journal of molecular sciences · 2023Review
- Exploring the bi-directional relationship and shared genes between depression and strokeFrontiers in genetics · 2023Article
- Article
- Ischemic Brain Neurodegeneration.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
In ischemic stroke patients, a higher monocyte count is associated with disease severity and worse prognosis. The complex correlation between subset phenotypes and functions underscores the importance of clarifying the role of monocyte subpopulations. We examined the subtype-specific distribution of the CD163+ and CD80+ circulating monocytes and evaluated their association with the inflammatory status in 26 ischemic stroke patients and 16 healthy controls. An increased percentage of CD163+/CD16+ and CD163+/CD14++ events occurred 24 and 48 h after a stroke compared to the controls. CD163+ expression was more pronounced in CD16+ non-classical and intermediate monocytes, as compared to CD14+ classical subtype, 24 h after stroke. Conversely, the percentage of CD80+/CD16+ events was unaffected in patients; meanwhile, the percentage of CD80+/CD14+ events significantly increased only 24 h after stroke. Interleukin (IL)-1beta, TNF-alpha, and IL-4 mRNA levels were higher, while IL-10 mRNA levels were reduced in total monocytes from patients versus controls, at either 24 h or 48 h after stroke. The percentage of CD163+/CD16+ events 24 h after stroke was positively associated with NIHSS score and mRS at admission, suggesting that stroke severity and disability are relevant triggers for CD163+ expression in circulating CD16+ monocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.